Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Unknown 2Terminated 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Thoracic 8Gastrointestinal 7Other hematologic neoplasm 5Tumor-Agnostic 4Breast 4Other solid neoplasm 2Gynecologic 2Sarcoma 1Myeloid 1Lymphoid 1

Conditions

Neoplasms 4Neoplasms, Second Primary 1Neoplasm Metastasis 1

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Antineoplastic Agents × Tumor-Agnostic × Clear all
NCT06877533 2025-08-12

A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors

iTeos Therapeutics

Phase 1 Terminated
3 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05467189 2022-07-20

Antineoplastic Drugs in Elderly Patients

Shandong University

Recruiting
500 enrolled
Tumor-Agnostic

Neoplasms

NCT04696250 2021-01-06

AVATAR

University Hospital, Caen

Unknown
5,000,000 enrolled
Tumor-Agnostic

Neoplasms

NCT03777930 2018-12-19

The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol

Shenzhen Fifth People's Hospital

Phase 4 Unknown
200 enrolled
Tumor-Agnostic

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡